Search
for
Sort by
Research 61–90 of 1000+
- Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline
- Guidelines on the use of finasteride in androgenetic alopecia
- International Consensus Guidelines on the Safe and Evidence-Based Practice of Mesotherapy: A Multidisciplinary Statement
- Guidelines for perioperative antithrombotic therapy in hair restoration surgery: management of patients with coronary heart disease, mechanical heart valve, and atrial fibrillation
- Low‐Dose Oral Minoxidil and Associated Adverse Events: Analyses of the FDA Adverse Event Reporting System (FAERS) With a Focus on Pericardial Effusions
- Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism
- British Association of Dermatologists living guideline for managing people with alopecia areata 2024
- Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion
- Comparison of Current International Guidelines for the Management of Alopecia Areata—Comprehensive Review
- Endocrine Management of Adult Gender-Dysphoric/Gender-Incongruent Persons: A Clinical Practice Guideline from Endocrine Society of India
- The Possible Role of Prescribing Medications, Including Central Nervous System Drugs, in Contributing to Male-Factor Infertility (MFI): Assessment of the Food and Drug Administration (FDA) Pharmacovigilance Database
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- The Wound Reporting in Animal and Human Preclinical Studies (WRAHPS) Guidelines
- Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system
- Simultaneous spectrophotometric determination of finasteride and tadalafil in recently FDA approved Entadfi™ capsules
- Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system
- A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
- A microscopy-based small molecule screen in primary neurons reveals neuroprotective properties of the FDA-approved anti-viral drug Elvitegravir
- A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System
- Development of validated methods for the simultaneous quantification of Finasteride and Tadalafil in newly launched FDA-approved therapeutic combination: greenness assessment using AGP, analytical eco-scale, and GAPI tools
- Management of the psychological comorbidities of dermatological conditions: practitioners' guidelines
- Off-label prescriptions: patient safety first
- 370 An analysis of androgenetic alopecia treatment content on Instagram and TikTok
- Development of Uniform Protocol for Alopecia Areata Clinical Trials
- The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials
- Expanding the Availability of Scalp Cooling to All Patients at Risk of Chemotherapy-Induced Alopecia
- Modern and Promising Strategies for Treatment of Alopecia in the United States: Clinical and Pharmacological, Marketing, Regulatory, SWOT Analysis
- Finasteride Use: Evaluation of Depression and Suicide Risk
- Monitoring and Evaluation of Temporary Increase in Hair Shedding Induced by Topical Minoxidil in Androgenetic Alopecia: A Multicenter Prospective Cohort Study
- Alopecia Areata: An Updated Review for 2023